Determinants of Bone Turnover Markers in Healthy Premenopausal Women

[1]  L. Melton,et al.  High Serum IGFBP‐2 Is Predictive of Increased Bone Turnover in Aging Men and Women , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[2]  M. Allende-Vigo.  The use of biochemical markers of bone turnover in osteoporosis. , 2007, Puerto Rico health sciences journal.

[3]  R. Lindsay,et al.  A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. , 2007, Bone.

[4]  Elizabeth Rosenberg,et al.  A cross-sectional study of bone turnover markers in healthy premenopausal women. , 2007, Bone.

[5]  J. Reginster,et al.  Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study. , 2005, The Journal of clinical endocrinology and metabolism.

[6]  M. Maricic,et al.  Clinical use of serum and urine bone markers in the management of osteoporosis , 2005, Current medical research and opinion.

[7]  M. Hochberg,et al.  Treatment With Once‐Weekly Alendronate 70 mg Compared With Once‐Weekly Risedronate 35 mg in Women With Postmenopausal Osteoporosis: A Randomized Double‐Blind Study , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[8]  D. Bauer,et al.  Change in Bone Turnover and Hip, Non‐Spine, and Vertebral Fracture in Alendronate‐Treated Women: The Fracture Intervention Trial , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[9]  J. Rodriguez-Portales,et al.  Ten years' experience with alendronate for osteoporosis in postmenopausal women. , 2004, The New England journal of medicine.

[10]  Mary L Bouxsein,et al.  The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. , 2003, The New England journal of medicine.

[11]  S. Adami,et al.  Prevalence of hypovitaminosis D in elderly women in Italy: clinical consequences and risk factors , 2003, Osteoporosis International.

[12]  R. Eastell,et al.  Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[13]  A. Di Spiezio Sardo,et al.  Effects of a low-dose and ultra-low-dose combined oral contraceptive use on bone turnover and bone mineral density in young fertile women: a prospective controlled randomized study. , 2003, Contraception.

[14]  M. Calvo,et al.  Patterns of osteocalcin and bone specific alkaline phosphatase by age, gender, and race or ethnicity. , 2002, Bone.

[15]  P. Delmas,et al.  Cross‐Sectional Evaluation of Bone Metabolism in Men * , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[16]  P. Delmas,et al.  Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis. , 2001, Clinical chemistry.

[17]  A. Paoletti,et al.  Evidence that treatment with monophasic oral contraceptive formulations containing ethinylestradiol plus gestodene reduces bone resorption in young women. , 2000, Contraception.

[18]  G G Klee,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1998 by The Endocrine Society Relationship of Serum Sex Steroid Levels and Bone Turnover Markers with Bone Mineral Density in Men and Women: A Key Role for Bioavailable Estroge , 2022 .

[19]  B. Riis,et al.  Low bone mass and fast rate of bone loss at menopause: equal risk factors for future fracture: a 15-year follow-up study. , 1997, Bone.

[20]  P. Delmas,et al.  Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[21]  P. Delmas,et al.  Decreased bone turnover in oral contraceptive users. , 1995, Bone.

[22]  W. O'Fallon,et al.  Long‐term fracture prediction by bone mineral assessed at different skeletal sites , 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[23]  I. Karl,et al.  Regulation of canine renal vesicle Pi transport by growth hormone and parathyroid hormone. , 1980, Biochimica et biophysica acta.

[24]  C. Christiansen,et al.  Six and Twelve Month Changes in Bone Turnover are Related to Reduction in Vertebral Fracture Risk During 3 Years of Raloxifene Treatment in Postmenopausal Osteoporosis , 2001, Osteoporosis International.

[25]  R. Eastell,et al.  The Use of Biochemical Markers of Bone Turnover in Osteoporosis , 2000, Osteoporosis International.

[26]  R. Eastell,et al.  Preanalytical Variability of Biochemical Markers of Bone Turnover , 2000, Osteoporosis International.

[27]  P. Garnero.  Markers of Bone Turnover for the Prediction of Fracture Risk , 2000, Osteoporosis International.